<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Success Stories - Detailed</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: Aptos, 'Segoe UI', sans-serif;
            background: white;
            padding: 40px 20px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
        }
        
        .title {
            font-size: 36px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 30px;
            text-align: center;
        }
        
        .success-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 20px;
            margin-bottom: 60px;
        }
        
        .success-card {
            background: linear-gradient(135deg, #f8f9fb 0%, #e8f2ff 100%);
            border: 3px solid #1E64C8;
            border-radius: 12px;
            padding: 22px;
            transition: all 0.3s;
        }
        
        .success-card:hover {
            transform: translateY(-8px);
            box-shadow: 0 12px 30px rgba(30, 100, 200, 0.25);
        }
        
        .success-title {
            font-size: 20px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 10px;
        }
        
        .success-drug {
            font-size: 16px;
            font-weight: 600;
            color: #333;
            margin-bottom: 8px;
        }
        
        .success-description {
            font-size: 15px;
            color: #555;
            line-height: 1.5;
        }
        
        .highlight {
            color: #1E64C8;
            font-weight: 600;
        }

        /* Detailed Section Styles */
        .detail-section {
            margin-bottom: 80px;
            padding: 40px;
            background: #f8f9fb;
            border-radius: 16px;
            border-left: 6px solid #1E64C8;
        }

        .detail-header {
            display: flex;
            align-items: center;
            margin-bottom: 30px;
            padding-bottom: 20px;
            border-bottom: 2px solid #1E64C8;
        }

        .detail-number {
            font-size: 48px;
            font-weight: 700;
            color: #1E64C8;
            margin-right: 20px;
            opacity: 0.3;
        }

        .detail-title-block {
            flex: 1;
        }

        .detail-title {
            font-size: 28px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 5px;
        }

        .detail-subtitle {
            font-size: 18px;
            color: #666;
            font-style: italic;
        }

        .content-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 40px;
            margin-top: 30px;
        }

        .diagram-box {
            background: white;
            padding: 30px;
            border-radius: 12px;
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }

        .diagram-title {
            font-size: 18px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 20px;
            text-align: center;
        }

        .mechanism-diagram {
            display: flex;
            flex-direction: column;
            align-items: center;
            gap: 15px;
        }

        .diagram-element {
            width: 100%;
            padding: 15px;
            background: linear-gradient(135deg, #e8f2ff 0%, #d0e8ff 100%);
            border: 2px solid #1E64C8;
            border-radius: 8px;
            text-align: center;
            font-weight: 600;
            color: #333;
        }

        .arrow {
            font-size: 24px;
            color: #1E64C8;
        }

        .info-box {
            background: white;
            padding: 30px;
            border-radius: 12px;
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }

        .info-section {
            margin-bottom: 20px;
        }

        .info-section:last-child {
            margin-bottom: 0;
        }

        .info-label {
            font-size: 14px;
            font-weight: 700;
            color: #1E64C8;
            text-transform: uppercase;
            margin-bottom: 8px;
        }

        .info-text {
            font-size: 15px;
            color: #333;
            line-height: 1.6;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 15px;
            margin-top: 20px;
        }

        .stat-box {
            background: linear-gradient(135deg, #e8f2ff 0%, #d0e8ff 100%);
            padding: 15px;
            border-radius: 8px;
            text-align: center;
        }

        .stat-value {
            font-size: 28px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 5px;
        }

        .stat-label {
            font-size: 13px;
            color: #666;
        }

        .timeline {
            display: flex;
            align-items: center;
            justify-content: space-between;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
        }

        .timeline-item {
            text-align: center;
            flex: 1;
        }

        .timeline-year {
            font-size: 20px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 5px;
        }

        .timeline-event {
            font-size: 13px;
            color: #666;
        }

        .timeline-arrow {
            font-size: 20px;
            color: #1E64C8;
            margin: 0 10px;
        }

        .key-points {
            background: #fff9e6;
            border-left: 4px solid #ffc107;
            padding: 20px;
            border-radius: 8px;
            margin-top: 20px;
        }

        .key-points-title {
            font-size: 16px;
            font-weight: 700;
            color: #f57c00;
            margin-bottom: 10px;
        }

        .key-points ul {
            list-style: none;
            padding-left: 0;
        }

        .key-points li {
            padding-left: 25px;
            position: relative;
            margin-bottom: 8px;
            color: #333;
            line-height: 1.6;
        }

        .key-points li:before {
            content: "âœ“";
            position: absolute;
            left: 0;
            color: #f57c00;
            font-weight: 700;
        }

        .molecular-diagram {
            display: flex;
            justify-content: space-around;
            align-items: center;
            padding: 20px;
            background: linear-gradient(135deg, #f8f9fb 0%, #e8f2ff 100%);
            border-radius: 8px;
            margin: 20px 0;
        }

        .molecule {
            text-align: center;
        }

        .molecule-visual {
            width: 80px;
            height: 80px;
            background: #1E64C8;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-weight: 700;
            font-size: 16px;
            margin: 0 auto 10px;
        }

        .molecule-label {
            font-size: 13px;
            color: #333;
            font-weight: 600;
        }

        .outcome-comparison {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin: 20px 0;
        }

        .outcome-box {
            padding: 20px;
            border-radius: 8px;
            text-align: center;
        }

        .outcome-before {
            background: #ffebee;
            border: 2px solid #ef5350;
        }

        .outcome-after {
            background: #e8f5e9;
            border: 2px solid #66bb6a;
        }

        .outcome-title {
            font-weight: 700;
            margin-bottom: 10px;
            font-size: 14px;
        }

        .outcome-value {
            font-size: 32px;
            font-weight: 700;
            margin: 10px 0;
        }

        @media print {
            .detail-section {
                page-break-inside: avoid;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="title">ðŸŽ¯ Precision Medicine Success Stories</div>
        
        <div class="success-grid">
            <div class="success-card">
                <div class="success-title">HER2+ Breast Cancer</div>
                <div class="success-drug">Trastuzumab (Herceptin)</div>
                <div class="success-description">
                    First companion diagnostic: <span class="highlight">HER2 testing</span> identifies patients who benefit from targeted therapy. Dramatically improved survival in HER2+ patients.
                </div>
            </div>
            
            <div class="success-card">
                <div class="success-title">CML Treatment Revolution</div>
                <div class="success-drug">Imatinib (Gleevec)</div>
                <div class="success-description">
                    Targeting <span class="highlight">BCR-ABL fusion</span> transformed CML from fatal to manageable chronic disease. 5-year survival >90%.
                </div>
            </div>
            
            <div class="success-card">
                <div class="success-title">MSI-High Cancers</div>
                <div class="success-drug">Pembrolizumab (Keytruda)</div>
                <div class="success-description">
                    First tissue-agnostic approval based on <span class="highlight">MSI biomarker</span>. Immunotherapy success across multiple cancer types.
                </div>
            </div>
            
            <div class="success-card">
                <div class="success-title">Melanoma Breakthrough</div>
                <div class="success-drug">BRAF Inhibitors</div>
                <div class="success-description">
                    <span class="highlight">BRAF V600E mutation</span> testing enables combination therapy. Median survival improved from 9 to 25+ months.
                </div>
            </div>
            
            <div class="success-card">
                <div class="success-title">CAR-T Cell Therapy</div>
                <div class="success-drug">Tisagenlecleucel (Kymriah)</div>
                <div class="success-description">
                    <span class="highlight">CD19+ B-cell</span> targeting in leukemia/lymphoma. Complete remission in 80%+ of refractory patients.
                </div>
            </div>
            
            <div class="success-card">
                <div class="success-title">ðŸ’¡ Key Lessons</div>
                <div class="success-description" style="margin-top: 10px;">
                    â€¢ Strong biomarker-target link<br>
                    â€¢ Rigorous validation studies<br>
                    â€¢ Drug-diagnostic co-development
                </div>
            </div>
        </div>

        <!-- Detailed Section 1: HER2+ Breast Cancer -->
        <div class="detail-section">
            <div class="detail-header">
                <div class="detail-number">01</div>
                <div class="detail-title-block">
                    <div class="detail-title">HER2+ Breast Cancer: Trastuzumab (Herceptin)</div>
                    <div class="detail-subtitle">The Pioneer of Companion Diagnostics</div>
                </div>
            </div>

            <div class="content-grid">
                <div class="diagram-box">
                    <div class="diagram-title">Mechanism of Action</div>
                    <div class="mechanism-diagram">
                        <div class="diagram-element">HER2 Overexpression<br><small>Gene amplification</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Excessive Cell Signaling<br><small>Uncontrolled growth</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Trastuzumab Binding<br><small>Blocks HER2 receptor</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Tumor Growth Inhibition<br><small>+ Immune activation</small></div>
                    </div>
                </div>

                <div class="info-box">
                    <div class="info-section">
                        <div class="info-label">Clinical Background</div>
                        <div class="info-text">
                            HER2 (Human Epidermal Growth Factor Receptor 2) is overexpressed in approximately 20-25% of breast cancers. This overexpression leads to aggressive tumor behavior and was historically associated with poor prognosis.
                        </div>
                    </div>

                    <div class="info-section">
                        <div class="info-label">Diagnostic Testing</div>
                        <div class="info-text">
                            Two primary methods: Immunohistochemistry (IHC) measures protein expression, and Fluorescence In Situ Hybridization (FISH) detects gene amplification. Patients must test positive to receive treatment.
                        </div>
                    </div>

                    <div class="info-section">
                        <div class="info-label">FDA Approval Timeline</div>
                        <div class="info-text">
                            1998: First companion diagnostic-drug combination approved. Revolutionized the concept of biomarker-driven therapy and paved the way for personalized medicine.
                        </div>
                    </div>
                </div>
            </div>

            <div class="outcome-comparison">
                <div class="outcome-box outcome-before">
                    <div class="outcome-title">Before Trastuzumab</div>
                    <div class="outcome-value" style="color: #ef5350;">Poor</div>
                    <div class="stat-label">HER2+ associated with<br>worst prognosis</div>
                </div>
                <div class="outcome-box outcome-after">
                    <div class="outcome-title">After Trastuzumab</div>
                    <div class="outcome-value" style="color: #66bb6a;">52%</div>
                    <div class="stat-label">Reduction in mortality<br>in metastatic disease</div>
                </div>
            </div>

            <div class="key-points">
                <div class="key-points-title">Key Success Factors</div>
                <ul>
                    <li>Strong biological rationale: Direct targeting of overexpressed receptor</li>
                    <li>Validated companion diagnostic: Standardized HER2 testing protocols</li>
                    <li>Multiple mechanisms: Receptor blockade + antibody-dependent cellular cytotoxicity</li>
                    <li>Combination potential: Effective with chemotherapy and other HER2-targeted agents</li>
                </ul>
            </div>
        </div>

        <!-- Detailed Section 2: CML Treatment -->
        <div class="detail-section">
            <div class="detail-header">
                <div class="detail-number">02</div>
                <div class="detail-title-block">
                    <div class="detail-title">Chronic Myeloid Leukemia: Imatinib (Gleevec)</div>
                    <div class="detail-subtitle">From Death Sentence to Chronic Disease</div>
                </div>
            </div>

            <div class="content-grid">
                <div class="diagram-box">
                    <div class="diagram-title">BCR-ABL Fusion & Targeting</div>
                    <div class="molecular-diagram">
                        <div class="molecule">
                            <div class="molecule-visual">BCR<br>Chr 22</div>
                            <div class="molecule-label">Normal BCR gene</div>
                        </div>
                        <div style="font-size: 24px; color: #1E64C8;">+</div>
                        <div class="molecule">
                            <div class="molecule-visual">ABL<br>Chr 9</div>
                            <div class="molecule-label">Normal ABL gene</div>
                        </div>
                        <div style="font-size: 24px; color: #1E64C8;">â†’</div>
                        <div class="molecule">
                            <div class="molecule-visual" style="background: #ef5350;">BCR-ABL</div>
                            <div class="molecule-label">Fusion protein</div>
                        </div>
                    </div>
                    <div class="mechanism-diagram" style="margin-top: 20px;">
                        <div class="diagram-element">BCR-ABL Fusion Protein<br><small>Constitutively active tyrosine kinase</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Imatinib Binding<br><small>ATP-competitive inhibition</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Kinase Activity Blocked<br><small>Halts malignant proliferation</small></div>
                    </div>
                </div>

                <div class="info-box">
                    <div class="info-section">
                        <div class="info-label">The Philadelphia Chromosome</div>
                        <div class="info-text">
                            The Philadelphia chromosome, resulting from a t(9;22) translocation, creates the BCR-ABL fusion gene. This was the first specific genetic abnormality linked to a human cancer, discovered in 1960.
                        </div>
                    </div>

                    <div class="stats-grid">
                        <div class="stat-box">
                            <div class="stat-value">95%</div>
                            <div class="stat-label">CML cases with Ph+</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">>90%</div>
                            <div class="stat-label">5-year survival rate</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">83%</div>
                            <div class="stat-label">Complete cytogenetic response</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">2001</div>
                            <div class="stat-label">FDA approval year</div>
                        </div>
                    </div>

                    <div class="info-section" style="margin-top: 20px;">
                        <div class="info-label">Diagnostic Requirements</div>
                        <div class="info-text">
                            PCR testing for BCR-ABL transcripts is required for diagnosis and monitoring. Quantitative PCR allows precise measurement of disease burden during treatment.
                        </div>
                    </div>
                </div>
            </div>

            <div class="timeline">
                <div class="timeline-item">
                    <div class="timeline-year">1960</div>
                    <div class="timeline-event">Philadelphia chromosome discovered</div>
                </div>
                <div class="timeline-arrow">â†’</div>
                <div class="timeline-item">
                    <div class="timeline-year">1990s</div>
                    <div class="timeline-event">BCR-ABL identified as target</div>
                </div>
                <div class="timeline-arrow">â†’</div>
                <div class="timeline-item">
                    <div class="timeline-year">2001</div>
                    <div class="timeline-event">Imatinib FDA approval</div>
                </div>
                <div class="timeline-arrow">â†’</div>
                <div class="timeline-item">
                    <div class="timeline-year">Present</div>
                    <div class="timeline-event">CML now chronic disease</div>
                </div>
            </div>

            <div class="key-points">
                <div class="key-points-title">Paradigm Shift in Cancer Treatment</div>
                <ul>
                    <li>Rational drug design: First successful molecular-targeted cancer therapy</li>
                    <li>Predictable biomarker: Single genetic alteration in >95% of cases</li>
                    <li>Dramatic efficacy: Transformed fatal disease to manageable condition</li>
                    <li>Proof of concept: Demonstrated viability of precision medicine approach</li>
                    <li>Resistance management: Led to development of second and third-generation TKIs</li>
                </ul>
            </div>
        </div>

        <!-- Detailed Section 3: MSI-High Cancers -->
        <div class="detail-section">
            <div class="detail-header">
                <div class="detail-number">03</div>
                <div class="detail-title-block">
                    <div class="detail-title">MSI-High Cancers: Pembrolizumab (Keytruda)</div>
                    <div class="detail-subtitle">First Tissue-Agnostic Cancer Therapy</div>
                </div>
            </div>

            <div class="content-grid">
                <div class="diagram-box">
                    <div class="diagram-title">MSI-High & Immunotherapy Response</div>
                    <div class="mechanism-diagram">
                        <div class="diagram-element">Mismatch Repair Deficiency<br><small>dMMR - Loss of MLH1, MSH2, MSH6, PMS2</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">High Microsatellite Instability<br><small>Accumulation of mutations</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Increased Tumor Mutational Burden<br><small>More neoantigens produced</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Enhanced Immune Recognition<br><small>Target for checkpoint inhibitors</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Pembrolizumab (Anti-PD-1)<br><small>Releases immune brake</small></div>
                    </div>
                </div>

                <div class="info-box">
                    <div class="info-section">
                        <div class="info-label">Revolutionary Approval</div>
                        <div class="info-text">
                            In 2017, FDA granted the first tissue/site-agnostic approval based on a common biomarker rather than tumor location. This marked a fundamental shift in cancer classification from anatomical to molecular.
                        </div>
                    </div>

                    <div class="info-section">
                        <div class="info-label">MSI-High Prevalence</div>
                        <div class="info-text">
                            Found in approximately 15% of colorectal cancers, 30% of endometrial cancers, and smaller percentages across many other cancer types including gastric, ovarian, and pancreatic cancers.
                        </div>
                    </div>

                    <div class="stats-grid">
                        <div class="stat-box">
                            <div class="stat-value">40%</div>
                            <div class="stat-label">Overall response rate in MSI-H</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">78%</div>
                            <div class="stat-label">Duration of response >6 months</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="outcome-comparison">
                <div class="outcome-box outcome-before">
                    <div class="outcome-title">MSI-Low / MSS Tumors</div>
                    <div class="outcome-value" style="color: #ef5350;"><5%</div>
                    <div class="stat-label">Response rate to<br>checkpoint inhibitors</div>
                </div>
                <div class="outcome-box outcome-after">
                    <div class="outcome-title">MSI-High Tumors</div>
                    <div class="outcome-value" style="color: #66bb6a;">40%</div>
                    <div class="stat-label">Response rate to<br>pembrolizumab</div>
                </div>
            </div>

            <div class="key-points">
                <div class="key-points-title">Breakthrough Significance</div>
                <ul>
                    <li>Tissue-agnostic approval: Treatment based on molecular signature, not tumor origin</li>
                    <li>Biomarker-driven selection: Strong predictive value of MSI-H/dMMR status</li>
                    <li>Pan-cancer application: Effective across multiple cancer types with MSI-H</li>
                    <li>Mechanistic understanding: High mutation burden creates immunogenic tumors</li>
                    <li>Diagnostic standardization: PCR and IHC methods widely available for MSI testing</li>
                    <li>Durable responses: Many patients achieve long-lasting disease control</li>
                </ul>
            </div>
        </div>

        <!-- Detailed Section 4: Melanoma BRAF -->
        <div class="detail-section">
            <div class="detail-header">
                <div class="detail-number">04</div>
                <div class="detail-title-block">
                    <div class="detail-title">Melanoma: BRAF Inhibitors</div>
                    <div class="detail-subtitle">Combination Therapy Success</div>
                </div>
            </div>

            <div class="content-grid">
                <div class="diagram-box">
                    <div class="diagram-title">BRAF V600E Mutation & Targeting</div>
                    <div class="mechanism-diagram">
                        <div class="diagram-element">BRAF V600E Mutation<br><small>Valine â†’ Glutamic acid at position 600</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Constitutive Kinase Activation<br><small>Continuous MAPK pathway signaling</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">BRAF Inhibitor (Vemurafenib/Dabrafenib)<br><small>Blocks mutant BRAF kinase</small></div>
                        <div style="font-size: 16px; margin: 10px 0; color: #1E64C8; font-weight: 600;">+ (Combination Therapy)</div>
                        <div class="diagram-element">MEK Inhibitor (Trametinib/Cobimetinib)<br><small>Blocks downstream signaling</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Tumor Regression + Reduced Resistance<br><small>Improved outcomes vs monotherapy</small></div>
                    </div>
                </div>

                <div class="info-box">
                    <div class="info-section">
                        <div class="info-label">BRAF Mutation in Melanoma</div>
                        <div class="info-text">
                            BRAF V600E mutation is present in approximately 50% of melanomas. This single point mutation leads to constitutive activation of the MAPK signaling pathway, driving uncontrolled cell proliferation.
                        </div>
                    </div>

                    <div class="info-section">
                        <div class="info-label">Evolution to Combination Therapy</div>
                        <div class="info-text">
                            Initial BRAF inhibitor monotherapy showed rapid responses but frequent resistance. Combining BRAF and MEK inhibitors significantly improved outcomes and delayed resistance development.
                        </div>
                    </div>

                    <div class="stats-grid">
                        <div class="stat-box">
                            <div class="stat-value">~50%</div>
                            <div class="stat-label">Melanomas with BRAF mutation</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">25+</div>
                            <div class="stat-label">Median survival (months) with combo</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">67%</div>
                            <div class="stat-label">Overall response rate</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">11</div>
                            <div class="stat-label">Median PFS (months)</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="timeline">
                <div class="timeline-item">
                    <div class="timeline-year">2002</div>
                    <div class="timeline-event">BRAF V600E mutation identified</div>
                </div>
                <div class="timeline-arrow">â†’</div>
                <div class="timeline-item">
                    <div class="timeline-year">2011</div>
                    <div class="timeline-event">Vemurafenib approved (monotherapy)</div>
                </div>
                <div class="timeline-arrow">â†’</div>
                <div class="timeline-item">
                    <div class="timeline-year">2014</div>
                    <div class="timeline-event">Combination therapy approved</div>
                </div>
                <div class="timeline-arrow">â†’</div>
                <div class="timeline-item">
                    <div class="timeline-year">Present</div>
                    <div class="timeline-event">Standard of care for BRAF+ melanoma</div>
                </div>
            </div>

            <div class="outcome-comparison">
                <div class="outcome-box outcome-before">
                    <div class="outcome-title">Before BRAF Inhibitors</div>
                    <div class="outcome-value" style="color: #ef5350;">9 mo</div>
                    <div class="stat-label">Median overall survival<br>in metastatic melanoma</div>
                </div>
                <div class="outcome-box outcome-after">
                    <div class="outcome-title">With BRAF+MEK Combo</div>
                    <div class="outcome-value" style="color: #66bb6a;">25+ mo</div>
                    <div class="stat-label">Median overall survival<br>nearly tripled</div>
                </div>
            </div>

            <div class="key-points">
                <div class="key-points-title">Clinical Impact & Lessons</div>
                <ul>
                    <li>Rapid response: Dramatic tumor shrinkage often within weeks of treatment</li>
                    <li>Companion diagnostics: Mandatory BRAF V600 mutation testing before treatment</li>
                    <li>Resistance mechanisms: Understanding led to combination strategy development</li>
                    <li>Synergistic effects: BRAF+MEK combination superior to monotherapy</li>
                    <li>Sequencing strategies: Integration with immunotherapy for optimal outcomes</li>
                    <li>Quality of life: Oral medications with manageable side effects</li>
                </ul>
            </div>
        </div>

        <!-- Detailed Section 5: CAR-T Cell Therapy -->
        <div class="detail-section">
            <div class="detail-header">
                <div class="detail-number">05</div>
                <div class="detail-title-block">
                    <div class="detail-title">CAR-T Cell Therapy: Tisagenlecleucel (Kymriah)</div>
                    <div class="detail-subtitle">Living Drug Revolution</div>
                </div>
            </div>

            <div class="content-grid">
                <div class="diagram-box">
                    <div class="diagram-title">CAR-T Manufacturing & Mechanism</div>
                    <div class="mechanism-diagram">
                        <div class="diagram-element">Patient T-Cell Collection<br><small>Leukapheresis procedure</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Genetic Engineering<br><small>Viral vector introduces CAR gene</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">CAR Expression<br><small>T-cells now target CD19</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Ex Vivo Expansion<br><small>Multiply CAR-T cells</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Infusion to Patient<br><small>CAR-T cells attack CD19+ cancer cells</small></div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element">Tumor Elimination<br><small>+ Long-term memory</small></div>
                    </div>
                </div>

                <div class="info-box">
                    <div class="info-section">
                        <div class="info-label">Revolutionary Approach</div>
                        <div class="info-text">
                            CAR-T represents a paradigm shift: a "living drug" that multiplies inside the patient and can provide long-lasting immunity. First gene therapy approved for cancer treatment in the United States (2017).
                        </div>
                    </div>

                    <div class="info-section">
                        <div class="info-label">CD19 Target Selection</div>
                        <div class="info-text">
                            CD19 is expressed on B-cells and most B-cell malignancies but not on stem cells, allowing for potential B-cell recovery after treatment. Present in ALL, DLBCL, and follicular lymphoma.
                        </div>
                    </div>

                    <div class="stats-grid">
                        <div class="stat-box">
                            <div class="stat-value">81%</div>
                            <div class="stat-label">CR rate in pediatric ALL</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">52%</div>
                            <div class="stat-label">CR rate in DLBCL</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">89%</div>
                            <div class="stat-label">Response duration >6 months</div>
                        </div>
                        <div class="stat-box">
                            <div class="stat-value">2017</div>
                            <div class="stat-label">FDA approval year</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="molecular-diagram">
                <div class="molecule">
                    <div class="molecule-visual" style="width: 100px; height: 100px; font-size: 14px;">Normal<br>T-Cell</div>
                    <div class="molecule-label">No tumor recognition</div>
                </div>
                <div style="font-size: 30px; color: #1E64C8;">â†’</div>
                <div class="molecule">
                    <div class="molecule-visual" style="width: 100px; height: 100px; background: #66bb6a; font-size: 14px;">CAR-T<br>Cell</div>
                    <div class="molecule-label">Engineered to target CD19</div>
                </div>
                <div style="font-size: 30px; color: #1E64C8;">â†’</div>
                <div class="molecule">
                    <div class="molecule-visual" style="width: 100px; height: 100px; background: #ef5350; font-size: 14px;">CD19+<br>Cancer</div>
                    <div class="molecule-label">Target cell eliminated</div>
                </div>
            </div>

            <div class="key-points">
                <div class="key-points-title">Clinical Considerations</div>
                <ul>
                    <li>Indication: Refractory or relapsed B-cell ALL and DLBCL after multiple therapies</li>
                    <li>Personalized manufacturing: Each dose custom-made from patient's own cells</li>
                    <li>Cytokine release syndrome: Major toxicity requiring careful monitoring and management</li>
                    <li>Neurotoxicity: CAR-T-related encephalopathy syndrome (CRES) in some patients</li>
                    <li>Durable remissions: Many patients achieve long-term disease-free survival</li>
                    <li>B-cell aplasia: Expected on-target effect requiring immunoglobulin replacement</li>
                    <li>Cost considerations: High upfront cost but potential for cure in refractory disease</li>
                </ul>
            </div>

            <div class="outcome-comparison">
                <div class="outcome-box outcome-before">
                    <div class="outcome-title">Historical Outcomes</div>
                    <div class="outcome-value" style="color: #ef5350;"><10%</div>
                    <div class="stat-label">Survival in refractory<br>pediatric ALL</div>
                </div>
                <div class="outcome-box outcome-after">
                    <div class="outcome-title">With CAR-T Therapy</div>
                    <div class="outcome-value" style="color: #66bb6a;">81%</div>
                    <div class="stat-label">Complete remission<br>rate achieved</div>
                </div>
            </div>
        </div>

        <!-- Detailed Section 6: Key Lessons -->
        <div class="detail-section">
            <div class="detail-header">
                <div class="detail-number">06</div>
                <div class="detail-title-block">
                    <div class="detail-title">Key Lessons from Precision Medicine Success</div>
                    <div class="detail-subtitle">Blueprint for Future Development</div>
                </div>
            </div>

            <div class="content-grid">
                <div class="diagram-box">
                    <div class="diagram-title">Success Framework</div>
                    <div class="mechanism-diagram">
                        <div class="diagram-element" style="background: linear-gradient(135deg, #e3f2fd 0%, #bbdefb 100%);">
                            <strong>1. Strong Biomarker-Target Link</strong><br>
                            <small>Clear biological rationale</small>
                        </div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element" style="background: linear-gradient(135deg, #e8f5e9 0%, #c8e6c9 100%);">
                            <strong>2. Validated Diagnostic Test</strong><br>
                            <small>Reliable, reproducible, standardized</small>
                        </div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element" style="background: linear-gradient(135deg, #fff3e0 0%, #ffe0b2 100%);">
                            <strong>3. Drug-Diagnostic Co-Development</strong><br>
                            <small>Parallel development pathway</small>
                        </div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element" style="background: linear-gradient(135deg, #f3e5f5 0%, #e1bee7 100%);">
                            <strong>4. Rigorous Clinical Validation</strong><br>
                            <small>Prospective studies with clear endpoints</small>
                        </div>
                        <div class="arrow">â†“</div>
                        <div class="diagram-element" style="background: linear-gradient(135deg, #e0f2f1 0%, #b2dfdb 100%);">
                            <strong>5. Regulatory Approval</strong><br>
                            <small>Companion diagnostic + drug</small>
                        </div>
                    </div>
                </div>

                <div class="info-box">
                    <div class="info-section">
                        <div class="info-label">Common Success Elements</div>
                        <div class="info-text">
                            All successful precision medicine approaches share: (1) actionable biomarkers with strong predictive value, (2) validated companion diagnostics, (3) targeted mechanism of action, (4) demonstrable clinical benefit in biomarker-selected populations.
                        </div>
                    </div>

                    <div class="info-section">
                        <div class="info-label">Evolution of Paradigm</div>
                        <div class="info-text">
                            From anatomical classification to molecular classification: Modern cancer treatment increasingly focuses on the molecular characteristics of tumors rather than their tissue of origin, as exemplified by tissue-agnostic approvals.
                        </div>
                    </div>

                    <div class="info-section">
                        <div class="info-label">Future Directions</div>
                        <div class="info-text">
                            Next generation approaches include: multi-omic biomarkers, liquid biopsies for real-time monitoring, AI-driven patient selection, combination biomarker strategies, and integration of germline and somatic testing.
                        </div>
                    </div>
                </div>
            </div>

            <div class="key-points">
                <div class="key-points-title">Critical Success Factors Across All Examples</div>
                <ul>
                    <li><strong>Biological Understanding:</strong> Deep mechanistic insight into disease pathogenesis and drug action</li>
                    <li><strong>Biomarker Validation:</strong> Analytical and clinical validation in large, well-designed studies</li>
                    <li><strong>Patient Selection:</strong> Clear criteria for identifying patients most likely to benefit</li>
                    <li><strong>Regulatory Framework:</strong> FDA guidance on companion diagnostics facilitated development</li>
                    <li><strong>Accessible Testing:</strong> Standardized, widely available diagnostic tests with quality control</li>
                    <li><strong>Clinical Evidence:</strong> Demonstrable improvement in patient outcomes in selected populations</li>
                    <li><strong>Resistance Management:</strong> Understanding and addressing mechanisms of treatment resistance</li>
                    <li><strong>Combination Strategies:</strong> Rational combinations based on complementary mechanisms</li>
                </ul>
            </div>

            <div class="stats-grid" style="margin-top: 30px;">
                <div class="stat-box">
                    <div class="stat-value">50+</div>
                    <div class="stat-label">FDA-approved companion diagnostics</div>
                </div>
                <div class="stat-box">
                    <div class="stat-value">100+</div>
                    <div class="stat-label">Targeted cancer therapies approved</div>
                </div>
                <div class="stat-box">
                    <div class="stat-value">30%</div>
                    <div class="stat-label">Cancer patients receive biomarker-guided therapy</div>
                </div>
                <div class="stat-box">
                    <div class="stat-value">Growing</div>
                    <div class="stat-label">Precision medicine market</div>
                </div>
            </div>

            <div class="key-points" style="background: #e3f2fd; border-left-color: #1E64C8; margin-top: 30px;">
                <div class="key-points-title" style="color: #1565c0;">Remaining Challenges</div>
                <ul>
                    <li>Access and equity: Ensuring all patients can access biomarker testing and targeted therapies</li>
                    <li>Tumor heterogeneity: Addressing intratumoral and intertumoral diversity</li>
                    <li>Resistance mechanisms: Developing strategies to overcome or prevent resistance</li>
                    <li>Rare biomarkers: Creating feasible development pathways for small patient populations</li>
                    <li>Cost sustainability: Balancing innovation with healthcare system affordability</li>
                    <li>Real-world implementation: Integrating complex testing into routine clinical practice</li>
                </ul>
            </div>
        </div>

    </div>
</body>
</html>